Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015

AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015